Losartan, an angiotensin type 1 receptor antagonist, improves endothelial function in non-insulin-dependent diabetes

Journal of the American College of Cardiology

Volumn 36, Issue 5, 2000, Pages 1461-1466

  Cheetham, Craig ^a   Collis, Julie ^a   O'Driscoll, Gerard ^b,c   Stanton, Kim ^b   Taylor, Roger ^a,b,c   Green, Daniel ^a,b,c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

^c Box X2213 GPO ^*  (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LOSARTAN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SCREENING; FEMALE; FOREARM BLOOD FLOW; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VASCULAR ENDOTHELIUM; VASCULAR RESISTANCE; VASODILATATION;

DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; ENDOTHELIUM; FEMALE; HUMANS; LOSARTAN; MALE; MIDDLE AGED; RECEPTORS, ANGIOTENSIN; REGIONAL BLOOD FLOW;

EID: 0034332787     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(00)00933-5     Document Type: Article

References (30)

1. Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus
2. Improvement in endothelial function by ACE inhibition in non-insulin-dependent diabetes mellitus
3. Reversing endothelial dysfunction with ACE inhibitors. A new TREND?
4. A randomised, placebo-controlled, double-blind study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension
5. Angiotensin receptor antagonist: Focus on losartan
6. 1) receptor antagonist: A review of its efficacy and safety in essential hypertension
7. Randomised trial of losartan versus captopril in patients over 65 with heart failure. (Evaluation of Losartan in the Elderly Study, ELITE)
8. Endothelium dependent vasomotor responses to endogenous agonists are potentiated following ACE inhibition by a bradykinin dependent mechanism
9. Endothelium-mediated vasodilation during ACE inhibition
10. Endothelium-derived relaxing factors and converting-enzyme inhibition
11. Role of bradykinin in mediating vascular effects of angiotensin converting enzyme inhibitors in humans
12. Bradykinin and the therapeutic actions of angiotensin converting enzyme inhibitors
13. Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus
14. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus
15. Impaired endothelium-dependent and independent dilation of forearm resistance arteries in men with diet-treated non-insulin-dependent diabetes: Role of dyslipidaemia
16. Obesity/insulin resistance is associated with endothelial dysfunction
17. Captopril improves impaired endothelium-dependent vasodilation in hypertensive patients
18. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: The TREND (Trial on Reversing Endothelial Dysfunction) study
19. Effect of angiotensin-converting enzyme inhibitors on endothelium-dependent peripheral vasodilation in patients with chronic heart failure
20. Effect of chronic angiotensin-converting enzyme inhibition on endothelial dysfunction in patients with chronic heart failure
21. Acute and long term effects of angiotensin type 1 receptor inhibition on endothelial dysfunction in atherosclerosis
22. Bradykinin-induced vasodilation of human coronary arteries in vivo: Role of nitric oxide and angiotensin converting enzyme
23. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects
24. Mechanisms by which Quinapril improves vascular function in coronary artery disease
25. Cellular and molecular mechanisms of endothelial cell dysfunction
26. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone
27. Angiotensin II stimulates macrophage-mediated oxidation of low-density lipoproteins
28. Insulin-stimulated production of nitric oxide is inhibited by wortmannin
29. Tetrahydrobiopterin metabolism in the streptozotocin induced diabetic state in rats
30. Acute amelioration of diabetic endothelial dysfunction with a derivative of the nitric oxide synthase cofactor, tetrahydrobiopterin